Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Tenes Paul

Internal Medicine Worcester, MA Doctor of Osteopathy

NPI 1881190809 CMS profile 10359999

55 Lake Ave N, Worcester, MA 01655

Open in the dashboard

General payments

$14,204

94 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tenes Paul of Worcester, MA is reported in the CMS Open Payments database as having received $14,204 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,773 41
2024 General $9,073 50
2023 General $235 1
2022 General $123 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tenes Paul
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Tenes Paul were reported at $4,773. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Tenes Paul Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $123 $141 $42–$496 $149
2023 $235 $149 $45–$519 $160
2024 $9,073 $154 $47–$537 $164
2025 $4,773 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $6,501 26 payments
  2. Abbott Laboratories $5,225 36 payments
  3. Biosense Webster, Inc. $1,195 14 payments
  4. Medtronic, Inc. $866 8 payments
  5. Abiomed $263 8 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $97 1 payment
  7. W. L. Gore & Associates, Inc. $56 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $9,774 41 payments
  2. Food and Beverage $3,492 47 payments
  3. Education $871 5 payments
  4. Grant $67 1 payment
Products named General payments · program years 2022–2025
  1. WATCHMAN Access System $2,310 6 payments
  2. ENSITE Structural Heart $2,127 17 payments
  3. ENSITE Electrophysiology $1,646 5 payments
  4. ENSITE PRECISION $1,217 13 payments
  5. FARAPULSE $1,198 6 payments
  6. Carto 3 $1,195 14 payments
  7. Micra $799 7 payments
  8. EMBLEM MRI S-ICD $352 2 payments
  9. Impella $263 8 payments
  10. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $235 1 payment
  11. Other $287 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

221

Median for Internal Medicine: 777

Drug cost

$53,535

Median for Internal Medicine: $73,373

Branded share of claims

36.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 21 $26,747
Entresto Sacubitril/Valsartan Brand 23 $23,589
Metoprolol Succinate Generic 32 $1,019
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 36 $576
Atorvastatin Calcium Generic 30 $495
Rosuvastatin Calcium Generic 20 $390
Ezetimibe Generic 16 $376
Carvedilol Generic 15 $127
Amlodipine Besylate Generic 13 $116
Spironolactone Generic 15 $100

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record